CRVS - Corvus Pharmaceuticals, Inc.
3.35
-0.215 -6.418%
Share volume: 710,461
Last Updated: 05-06-2025
Pharmaceutical Products/Pharmaceutical Preparations:
-0.13%
PREVIOUS CLOSE
CHG
CHG%
$3.56
-0.21
-0.06%
View ratios
| Fiscal Date | 03-31-2024 | 06-30-2024 | 09-30-2024 | 12-31-2024 | |
|---|---|---|---|---|---|
| Fiscal Quarter | Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | |
| Report Date | 05-07-2024 | 08-06-2024 | 11-12-2024 | 03-25-2025 | |
| Total revenue | 0.000 | 0.000 | 0.000 | 0.000 | |
| Cost of revenue | 0.000 | 0.000 | 0.000 | 0.000 | |
| Gross profit | 0.000 | 0.000 | 0.000 | 0.000 | |
| nan% | nan% | nan% | |||
| Operating expenses | 6.253 M | 5.935 M | 7.255 M | 8.105 M | |
| Selling general and admin | 2.178 M | 1.821 M | 2.033 M | 2.131 M | |
| Research and development | 4.075 M | 4.114 M | 5.222 M | 5.974 M | |
| Total expenses | 6.253 M | 5.935 M | 7.255 M | 8.100 M | |
| -5.09% | 22.24% | 11.65% | |||
| Operating income | -6.253 M | -5.935 M | -7.255 M | -8.105 M | |
| Ebit | -6.253 M | -4.119 M | -40.101 M | -10.452 M | |
| Pretax income | -5.937 M | -3.685 M | -39.535 M | -9.939 M | |
| -37.93% | 972.86% | -74.86% | |||
| Income tax | 0.000 | 0.000 | 0.000 | 0.000 | |
| Net income basic | 0.000 | 0.000 | 0.000 | 0.000 | |
| Net income | -5.701 M | -4.262 M | -40.217 M | -12.113 M | |
| 25.24% | -843.62% | 69.88% |
